Last reviewed · How we verify
Bupivacaine-adrenaline — Competitive Intelligence Brief
marketed
Local anesthetic with vasopressor
Voltage-gated sodium channels; alpha-1 adrenergic receptors (adrenaline component)
Anesthesia/Pain Management
Small molecule
Live · refreshed every 30 min
Target snapshot
Bupivacaine-adrenaline (Bupivacaine-adrenaline) — University of Aarhus. Bupivacaine is a local anesthetic that blocks sodium channels in nerve fibers, while adrenaline (epinephrine) causes vasoconstriction to prolong anesthetic duration and reduce systemic toxicity.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Bupivacaine-adrenaline TARGET | Bupivacaine-adrenaline | University of Aarhus | marketed | Local anesthetic with vasopressor | Voltage-gated sodium channels; alpha-1 adrenergic receptors (adrenaline component) | |
| Bupivacaine 0.25% with Epinephrine | Bupivacaine 0.25% with Epinephrine | Holy Cross Hospital, Florida | marketed | Local anesthetic with vasopressor | Voltage-gated sodium channels | |
| Bupivacaine 0.5 % with Epinephrine | Bupivacaine 0.5 % with Epinephrine | Holy Cross Hospital, Florida | marketed | Local anesthetic with vasopressor | Voltage-gated sodium channels | |
| Bupivicaine + epinephrine | Bupivicaine + epinephrine | Rush University Medical Center | marketed | Local anesthetic with vasopressor | Voltage-gated sodium channels; alpha and beta-adrenergic receptors | |
| Bupivacaine-epinephrine | Bupivacaine-epinephrine | Lumbini Medical College | marketed | Local anesthetic with vasopressor | Voltage-gated sodium channels; alpha-1 and beta-2 adrenergic receptors | |
| Lidocaine plus adrenaline | Lidocaine plus adrenaline | University of Santiago de Compostela | marketed | Local anesthetic with vasopressor | Voltage-gated sodium channels; alpha-1 and beta-1 adrenergic receptors | |
| Articaine / EPINEPHrine Cartridge | Articaine / EPINEPHrine Cartridge | Universidad de Antioquia | marketed | Local anesthetic with vasopressor | Voltage-gated sodium channels (articaine); alpha-1 and beta-1 adrenergic receptors (epinephrine) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Local anesthetic with vasopressor class)
- Holy Cross Hospital, Florida · 2 drugs in this class
- Lumbini Medical College · 1 drug in this class
- Rush University Medical Center · 1 drug in this class
- Universidad de Antioquia · 1 drug in this class
- University of Aarhus · 1 drug in this class
- University of Santiago de Compostela · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Bupivacaine-adrenaline CI watch — RSS
- Bupivacaine-adrenaline CI watch — Atom
- Bupivacaine-adrenaline CI watch — JSON
- Bupivacaine-adrenaline alone — RSS
- Whole Local anesthetic with vasopressor class — RSS
Cite this brief
Drug Landscape (2026). Bupivacaine-adrenaline — Competitive Intelligence Brief. https://druglandscape.com/ci/bupivacaine-adrenaline. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab